Here's Why CRISPR Therapeutics Stock Climbed 34% in February

CRISPR Therapeutics (CRSP -0.92%) was a standout in the market last month as its shares charged 34% higher, according to data provided by S&P Global Market Intelligence. The biotech stock sustained its momentum from prior months with a strong quarterly report and encouraging news from regulators.CRISPR keeps the good news rollingThere wasn't any transformative news out of CRISPR Therapeutics last month. Instead, the company sustained the excitement generated by important regulatory approvals over the past f ...